The insider sales are small relative to market cap and likely routine profit-taking or liquidity-driven, especially given the positive earnings catalyst. However, the cluster includes the CEO and COO selling immediately after a PRV-driven earnings beat, monitor for any additional insider sales in the next 30 days; a continuation would increase bearish signal. The stock's 55% analyst bullish consensus and $283.7M cash runway provide a fundamental floor, but the lack of insider buying at these depressed levels is a subtle negative.
Drug in focus
RCKT drug pipeline →RP-A501
● Neutral Named in this insider cluster- Impact
- Phase
- Phase 2 (pivotal/registrational)
- Time to market
- If the pivotal Phase 2 trial succeeds, a BLA submission for accelerated approval could follow in 2028-2029, given the 12-month endpoint timeline with last patient dosed by mid-2027.
- Next catalyst
- None dated
What to watchWatch for updates on enrollment of the remaining 9 patients in the pivotal Phase 2 trial and any interim data presentations at medical conferences in 2027. The FDA alignment in September 2026 de-risked the regulatory path, but the stock near its 52-week low reflects lingering safety concerns and a long wait until topline data (likely 2028). KRESLADI commercial traction is a separate value driver that could support the stock in the interim.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 18 $3.34entry
- T+1 · 3mo ago +9.28%α +9.07% · $3.65
- T+5 · 3mo ago +13.17%α +13.37% · $3.78
- T+20 · 2mo ago +4.49%α +5.48% · $3.49
- T+60 · 6d ago −26.65%α −24.61% · $2.45
Price Chart
How similar events traded
Executive Summary
Three Rocket Pharmaceuticals insiders, including the CEO and COO, sold a total of $154K in open-market sales over a 7-day window following the company's Q2 2026 earnings release. The earnings report showed a GAAP net income of $123.2M driven by a $178.2M PRV sale, but the insider selling cluster, particularly the COO's $128K sale, suggests insiders are taking profits or lack conviction in the stock's near-term upside at the current ~$3.50 price level. The total dollar value is 0.04% of the $381M market cap, which is trivial and likely routine, but the cluster's proximity to positive earnings and the CEO's participation warrants attention.
Key Financial Metrics
Key Facts
- CEO Shah Gaurav sold 2,837 shares at $3.381 for ~$10K on 2026-08-13.
- COO Stevens Christopher James sold 36,658 shares at $3.499 for ~$128K on 2026-08-11.
- General Counsel Wilson Martin sold 3,493 shares at $3.381 for ~$12K on 2026-08-13.
- Total insider sales of $154K represent 0.04% of RCKT's $381M market cap, trivial by proportionality standards.
- Sales occurred 3-7 days after Q2 2026 earnings showing a $123.2M GAAP net income, driven by a $178.2M PRV sale.
- The company ended Q2 2026 with $283.7M cash, extending runway into Q2 2028.
Financial Impact
Total insider sales of $154K, or 0.04% of market cap, are immaterial to the company's financial position.
Risk Factors
- Insider selling cluster may signal lack of confidence in near-term stock appreciation despite positive earnings.
- The $178.2M PRV gain is non-recurring; core operating loss of $46.9M in Q2 2026 still indicates cash burn.
- Stock price at ~$3.50 is near 52-week lows; further insider sales could exacerbate selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RCKT-1787004115933 |
Track record
21 reports on RCKT
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers